High-Performance Liquid Chromatographic Determination and Pharmacokinetics of Methyl N-[5[[4-(2-Pyridinyl)-l-piperazinyl]carbonyl]-1H-benzimidazol-2-yl] Carbamate (CDRI Compound 81-470), a New Anthelmintic Agent in Rats

Pharmaceutical Research -     

复方甲硝唑口腔复合膜的制备及质量控制

复方甲硝唑口腔复合膜以ＰＶＡ＿（１７～８８）－ＣＭＣＮａ（２：１）为药膜材料、ＰＶＡ＿（１７～８８）为覆盖膜材料，采用涂膜法制备，用紫外分光光度法测定含量平均回收率１０２．９％，Ｒ８０＝１．１６％。     

藏药雪灵芝研究进展

讨论雪灵芝在藏药中的特定含义,综述了雪灵芝的药用沿革、药理活性、化学成分研究进展,提出雪灵芝深入研究开发的方向。     

灯盏细辛对青光眼神经保护作用的临床研究

目的　评价灯盏细辛对眼压已控制的青光眼神经保护作用。方法　采用前瞻性、随机、双盲、安慰剂对照的研究方法 ,将眼压已控制的中晚期青光眼患者共 45例 ( 4 5眼 ) ,分层随机分为年龄匹配的灯盏细辛治疗组 ( 2 3例 )和安慰剂对照组 ( 2 2例 )。治疗组口服灯盏细辛 (EBHM) 2片 ,3次 /d ,对照组口服安慰剂 ,连续 6个月 ,每月复诊 1次。治疗前及每月复诊均检查矫正视力、眼压、视乳头杯盘比 (C/D)、自动静态阈值视野、血压和脉搏。结果　EBHM组与对照组在 6个月中平均眼压分别为 14 17mmHg± 2 5 0mmHg( 8～ 2 1mmHg)和 14 5 2mmHg± 1 94mmHg( 8～ 19mmHg) (P =0 5 98)。治疗 6个月后EBHM组平均敏感度 (MS)增加 1 42dB ,对照组MS下降 0 95dB(P =0 0 0 0 )。EBHM组和对照组视野进步率分别为 5 6 5 2 %和 4 5 5 % (P =0 0 0 1)。结论　灯盏细辛为一安全、无毒副作用的中草药 ,具有提高青光眼患者MS和部分改善原有视野缺损的作用 ,可作为视神经保护剂应用于治疗眼压已控制的青光眼。     

复方替硝唑单向缓释药膜的研制及其释放特性

本实验以保护膜和药物膜制备复方替硝唑单向缓释药膜（以下简称药膜），并通过双室恒温卡口渗透池研究药膜及药膜透过粘膜的药物释放情况，结果表明：药膜有良好的单向释放及单向透过粘膜释放药物的特性。药物透过粘膜的量随时间的延长而增加，5min及60min透过粘膜释放药物的累积百分率分别为（15．29±5．77）％，（6．25±2．96）％。     

Degranulation of Mast Cells in the Chick Chorioallantoic Membrane Does Not Increase Macromolecular Extravasation During Normal Angiogenesis

Objective : To test the hypothesis that stimulation of mast cell degranulation during normal angiogenesis in the chick chorioallantoic membrane (CAM) serves to acutely activate macromolecular transendothelial pathways. Methods : Using shell-less cultures of 6-day-old chick embryos, efflux of fluorescein isothiocyanate (FITC)-dextran 150 from CAM microvessels was evaluated, after applications of compound 48/80 or exogenous histamine, by computer-assisted videodensitometric analyses. Real-time confocal imaging enabled optical differentiation of first-order pre- and postcapillaries from the capillary networks. Cytologic ultrastructure of the microvascular units was also evaluated. Results : Although endogenous histamine was measurable and its concentration was increased after application of compound 48/80, segmental endothelia of the CAM microvascular units consistently restricted extravasation of FITC-dextran 150. Furthermore, intravascular injections of histamine also failed to induce interendothelial gap formation or macromolecular flux across the segmental CAM endothelia. Conclusions : These results are consistent with the interpretation that histamine-activated transendothelial pathways are inactive in the CAM at day 6. Whether such inactivity serves to retard facilitation of CAM angiogenesis by activated mast cells remains to be tested.     

InfluenceofQingdaiCompoundCapsule（复方青黛胶囊）ontheExpressionofc－mycinPsoriaticKeratinocytes

ＩｎｆｌｕｅｎｃｅｏｆＱｉｎｇｄａｉＣｏｍｐｏｕｎｄＣａｐｓｕｌｅ（复方青黛胶囊）ｏｎｔｈｅＥｘｐｒｅｓｓｉｏｎｏｆｃ－ｍｙｃｉｎＰｓｏｒｉａｔｉｃＫｅｒａｔｉｎｏｃｙｔｅｓＩｎｆｌｕｅｎｃｅｏｆＱｉｎｇｄａｉＣｏｍｐｏｕｎｄＣａｐｓｕｌｅ（复方青黛...     

Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-responsiveness in stabilized asthmatic children: a randomized, double-blind clinical trial.

Traditional Chinese medicine has a long history of application in the treatment of bronchial asthma. Solid scientific evidence, however, is not available despite its widespread use among patients worldwide and in Taiwan. To assess the effect of Ding Chuan Tang (DCT) in airway hyper-responsiveness (AHR) on asthmatic children via randomized, double blind, placebo-controlled clinical trial. This study enrolled children who were aged 8-15 and diagnosed as mild to moderate persistent asthma patients. They were randomly allocated to receive 6.0 g DCT or placebo daily for 12 wk. Self-recorded daily symptom scores, medication scores, and morning and evening peak expiratory flow rates were returned at the monthly clinic. Pulmonary function test, methacholine challenge test, and serum inflammatory mediators were measured before and at the end of the trial. Fifty-two asthmatic children completed the clinical study. Twenty-eight patients were assigned to the treatment group and 24 to the placebo group. At the end of the treatment period, AHR determined by log PC(20) was significantly improved in the DCT group (0.51 +/- 1.05 mg/ml vs. 0.26 +/- 0.84 mg/ml, p = 0.034). The total clinical and medication reduced parameters showed improvement in the DCT group (p = 0.004). The AHR, symptom and medication scores in children with persistent asthma were significantly improved with DCT treat for 12 wk. The results suggested more stable airways achieved with such an add-on complementary therapy.     

猕猴桃复方口服液和/或运动对大鼠降脂效果的实验研究

为了解服用猕猴桃复方口服液对高脂血症的预防和治疗效果及其与抗脂质过氧化的关系、并观察其与运动训练两种措施同时使用时的降脂效果，我们以８０只雄性Ｗｉｓｔａｒ大鼠为实验动物，在喂饲高脂饲料建立高脂血症模型的同时及建成高脂血症模型后，给予猕猴桃复方口服液或／和运动训练措施，采用体重、体脂（肾周及辜周脂肪重量）、血清总胆固醇（ＴＣ）、甘油三酯（ＴＧ）、高密度脂蛋白（ＨＤＬ－Ｃ）、氏密度脂蛋白（ＬＤＬ－Ｃ）、超氧化物歧化酶（ＳＯＤ）、丙二醛（ＭＤＡ）等指标，进行研究，主要结果如下：１．服用猕猴桃复方口服液或运动对喂饲高脂饲料大鼠均有抑制大鼠体重、体脂、血清胆固醇、甘油三酯、ＬＤＬ－Ｃ水平增加，提高血清高密度脂蛋白胆固醇（ＨＤＬ－Ｃ）水平的良好作用。２．猕猴桃复方口服液结合运动两因素联合使用时，对喂饲高脂饲料大鼠降低体重、体脂、血清胆固醇、甘油酯、血清低密度脂蛋白胆固醇（ＬＤＬ－Ｃ）水平和提高血清高密度脂蛋白胆固醇（ＨＤＬ－Ｃ）水平的效果比单独服用猕猴桃复方口服液或单独运动更好。３．在建立高脂血症大鼠模型同时，服用猕猴桃复方口服液或单一运动的预防性降脂效果优于在建成高脂血症模型后再使用这两种降脂措施的治疗效果。４．在大?     

叶下珠复方对四氯化碳所致小鼠肝损伤的保护作用及影响

目的：探讨叶下珠复方对小鼠实验性肝损伤的保护作用。方法：用CCl4诱导小鼠急慢性肝损伤模型，将实验小鼠分为空白对照组，CCl4模型组，西药对照组,吾下珠复方高，中,低剂量组（分别含生药60，30，15g/kg小鼠体重），西药在急，慢性肝损伤实验分别为联苯双酯和秋水仙碱，检测血清中的谷丙转氨酶（ALT），超氧化物歧化酶（SOD）的含量，观察肝组织病理改变。结果：所检测的各指标值CCl4模型组和正常组比差异有显意义（P＜0．01）；叶下珠复方各剂量组均可显降低血清中ALT和提高SOD含量，在急性肝损伤实验中，复方大，中剂量对降低ALT的效果与联苯双酯相似（P＞0．05），但复方大剂量提高SOD的效果优于联苯双酯；而在慢性肝损伤实验中，叶下珠复方大剂量降低ALT和SOD的效果优于秋水仙碱（P＜0．05），病理检查证实叶下珠复方各剂量组还可明显减轻肝细胞损伤程度。结论：叶下珠复方有很好的保护肝细胞作用。